{"id":10113,"date":"2022-11-24T07:00:00","date_gmt":"2022-11-24T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/"},"modified":"2022-11-24T07:00:00","modified_gmt":"2022-11-24T06:00:00","slug":"irlab-presenterar-pa-redeye-life-science-day-2022","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/","title":{"rendered":"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022"},"content":{"rendered":"<p>[mfn_before_post]<\/p>\n<div class=\"mfn-preamble\">\n<p><strong>G\u00f6teborg, Sverige, 24 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget presenterar och deltar p\u00e5 Redeye Life Science Day 2022 som h\u00e5lls p\u00e5 torsdagen den 24 november 2022.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Richard Godfrey, VD, deltar i en intervju kl. 11:40 den 24 november 2022. En f\u00f6rinspelad bolagspresentation finns tillg\u00e4nglig p\u00e5 eventplattformen. F\u00f6lj eventet live p\u00e5 <a target=\"_blank\" href=\"https:\/\/www.redeye.se\/events\/850947\/redeye-life-science-day\" rel=\"nofollow noopener\">https:\/\/www.redeye.se\/events\/850947\/redeye-life-science-day<\/a>.<br \/>\u00a0<br \/>En inspelning av intervjun och presentationen kommer att g\u00f6ras tillg\u00e4nglig p\u00e5 bolagets webbplats, <a href=\"http:\/\/www.irlab.se\" target=\"_blank\" rel=\"nofollow noopener\">www.irlab.se<\/a>, efter eventet.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-3931160317df\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information:<\/strong><\/p>\n<hr \/>\n<p>Richard Godfrey, VD<br \/>Telefon: +46 730 70 69 00<br \/>E-mail:\u00a0<a href=\"mailto:richard.godfrey@irlab.se\" target=\"_blank\" rel=\"nofollow noopener\">richard.godfrey@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-a19a8f82b785\">\n<p><strong class=\"mfn-heading-1\">Om IRLAB<\/strong><\/p>\n<hr \/>\n<p>IRLAB uppt\u00e4cker och utvecklar nya l\u00e4kemedel f\u00f6r behandling av Parkinsons sjukdom och andra sjukdomar i hj\u00e4rnan. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och pirepemat (IRL752) \u00e4r b\u00e5da i Fas IIb och \u00e4r designade f\u00f6r att behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinson. \u00c5r 2021 f\u00f6rv\u00e4rvade Ipsen, ett specialty pharma-bolag, de exklusiva globala r\u00e4ttigheterna till utveckling och kommersialisering av mesdopetam.<br \/>\u00a0<br \/>IRLAB har genererat alla sina l\u00e4kemedelskandidater och forts\u00e4tter att uppt\u00e4cka innovativa l\u00e4kemedelskandidater f\u00f6r behandling av neurologiska sjukdomar genom den egenutvecklade forskningsplattformen ISP (Integrative Screening Process). F\u00f6rutom IRLAB:s starka kliniska pipeline driver bolaget tv\u00e5 prekliniska program, IRL942 och IRL757, mot Fas I-studier. IRLAB \u00e4r noterat p\u00e5 Nasdaq Stockholm. Mer information p\u00e5\u00a0<a href=\"http:\/\/www.irlab.se.\/\" target=\"_blank\" rel=\"nofollow noopener\">www.irlab.se.<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/a330e23c-8bb0-4c2f-92a4-f4ba5c645b8a\/irlab-presenterar-pa-redeye-life-science-day-2022.pdf\" target=\"_blank\" rel=\"nofollow noopener\">IRLAB presenterar p\u00e5 Redeye Life Science Day 2022<\/a><\/p>\n<\/div>\n<p>[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>G\u00f6teborg, Sverige, 24 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget presenterar och deltar p\u00e5 Redeye Life Science Day 2022 som h\u00e5lls p\u00e5 torsdagen den 24 november 2022.<\/p>\n","protected":false},"template":"","class_list":["post-10113","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 24 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget presenterar och deltar p\u00e5 Redeye Life Science Day 2022 som h\u00e5lls p\u00e5 torsdagen den 24 november 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/\",\"name\":\"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2022-11-24T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB","og_description":"G\u00f6teborg, Sverige, 24 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att bolaget presenterar och deltar p\u00e5 Redeye Life Science Day 2022 som h\u00e5lls p\u00e5 torsdagen den 24 november 2022.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/","name":"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2022-11-24T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-life-science-day-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB presenterar p\u00e5 Redeye Life Science Day 2022"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/10113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=10113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}